Lexicon Pharmaceuticals | LXRX - Operating Profit


Lexicon Pharmaceuticals reported $-14.78M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Abbott USD 1.85B 399M Mar/2026
Acadia Pharmaceuticals USD -4.62M 22.01M Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alnylam Pharmaceuticals USD 137.59M 108.19M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 9.78B 792M Mar/2026
Esperion Therapeutics USD 85.23M 95.19M Dec/2025
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Illumina USD 239M 17M Mar/2026
Insmed USD -200.28M 49.43M Mar/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
J&J USD 6.62B 1.03B Mar/2026
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
MacroGenics USD -12.1M 30.74M Dec/2025
MannKind USD -76.99M 7.75M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Moderna USD -1.39B 531M Mar/2026
Novartis USD 4.24B 171M Mar/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sarepta Therapeutics USD 358.43M 768.52M Mar/2026
Thermo Fisher Scientific USD 1.91B 389M Mar/2026
Ultragenyx Pharmaceutical USD -216M 102M Mar/2026
United Therapeutics USD 325.8M 340.4M Mar/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024